Delving into the Latest Updates on LASSBio-1483 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms-

Target-

Action-

Mechanism-

Therapeutic Areas

Infectious DiseasesSkin and Musculoskeletal DiseasesOther Diseases

Active Indication-

Inactive Indication

LeishmaniasisTrypanosomiasis

Originator Organization

Federal University of Rio de Janeiro

Active Organization-

Inactive Organization

Federal University of Rio de Janeiro

License Organization-

Drug Highest PhasePendingPreclinical

First Approval Date-

Regulation-

Structure/Sequence

Molecular FormulaC12H9ClN4O4

InChIKeyRLCMPUDOYUZXHB-VGOFMYFVSA-N

CAS Registry1802058-27-0

Trypanosomatids are protozoan parasites that cause various diseases in human, such as leishmaniasis, Chagas disease and sleeping sickness. The highly syntenic genomes of the trypanosomatid species lead the assumption that they can encode similar proteins, indicating the possibility to design new antitrypanosomatid drugs with dual trypanosomicidal and leishmanicidal activities. In this work a series of compounds (6a-h and 7a-h), containing a semicarbazone scaffold as a peptide mimetic framework, was designed and synthesized. From this series compound 7g (LASSBio-1483) highlighted, showing dual in vitro trypanosomicidal and leishmanicidal activities, with potency similar to the standard drugs nifurtimox and pentamidine. This data, taken together with its good in silico druglikeness profile and its great chemical and plasma stability, make LASSBio-1483 (7g) a new antitrypanosomatid lead-candidate.

100 Deals associated with LASSBio-1483

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Leishmaniasis	Preclinical	Brazil	Federal University of Rio de Janeiro	01 Jul 2015
Trypanosomiasis	Preclinical	Brazil	Federal University of Rio de Janeiro	01 Jul 2015